Protagonist Therapeutics, Inc.
PTGX
Rank in Stocks
#2251
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Share Price
$138.50
Last synced: 2026-10-20
Market Cap
$8.96B
Change (1 day)
3.02%
Change (1 year)
84.67%
Country
US
Trade Protagonist Therapeutics, Inc. (PTGX)
Category
Healthcare
Revenue for Protagonist Therapeutics, Inc. (PTGX)
Revenue in Jun 2026 TTM: $281.99M
According to Protagonist Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is $281.99M. In 2023 the company made a revenue of $60.00M an increase over the revenue in the year 2022 that was $26.58M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Protagonist Therapeutics, Inc. from 2014 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $281.99M | -35.09% |
| 2024 | $434.43M | 624.06% |
| 2023 | $60.00M | 125.73% |
| 2022 | $26.58M | -2.84% |
| 2021 | $27.36M | -4.44% |
| 2020 | $28.63M | 12,293.07% |
| 2019 | $231.00K | -99.25% |
| 2018 | $30.93M | 54.14% |
| 2017 | $20.06M | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 4,376.83% |
US
|
|
| $2.23B | 690.09% |
US
|
|
| $15.74B | 5,483.25% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 2,035.27% |
NL
|
